DUBLIN–(BUSINESS WIRE)–The “Non-Alcoholic Steatohepatitis Treatment Market, by Drug, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.
This report provides an in-depth analysis of the global nonalcoholic steatohepatitis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
By 2050, this is projected at >29 million people – a 165% increase over the 2000 level. It is to be noted that these projections imply a steady increase in the overall prevalence of diabetes, from 3.99% in 2000 to 7.21% in 2050.
However, diagnosis of the nonalcoholic steatohepatitis can be difficult to capture in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global nonalcoholic steatohepatitis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global nonalcoholic steatohepatitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nonalcoholic steatohepatitis treatment market
Company Profiles:
- AstraZeneca Plc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Conatus Pharmaceuticals
- Enzo Biochem, Inc.
- GENFIT SA
- Galmed Pharmaceuticals Ltd.
- Gilead Science
- Immuron Ltd.
- Intercepts Pharmaceuticals
- Novo Nordisk
- Raptor Pharmaceutical Corporation
- Tobira Therapeutics, Inc.
Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Publisher Opportunity Map
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
- Pipeline Product Analysis
- Epidemiology Study
Global Nonalcoholic Steatohepatitis Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
Detailed Segmentation:
Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
- Cenicriviroc
- Elafibranor
- Ocaliva (Obeticholic Acid)
- Selonsertib
Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Nonalcoholic Steatohepatitis Treatment Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
For more information about this report visit https://www.researchandmarkets.com/r/t0uc4y
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900